Bimiralisib

small molecule

Identifier: CI-DRUG-00000818
Entity page: /drug/bimiralisib ↗
Edges: 24

Neighbours: 11 cancers10 trials
Drawn: 21 of 21 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Bimiralisib investigated for …INVESTIGATED_FOR6 of 6
→ investigated for	Squamous Cell Carcinomahistology	unknown	2	Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	2

Bimiralisib investigated in trials for …INVESTIGATED_IN_TRIALSderived8 of 8
→ investigated in trials for	Lymphomacancer_family 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Central Nervous System Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Central Nervous System Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastomasubtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphomahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Bimiralisib investigated in trials for …INVESTIGATED_IN_TRIALSderived8 of 8

→ investigated in trials for

Lymphomacancer_family

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lymphoma

Observed

Bimiralisib studied in …STUDIED_INderived10 of 10
→ studied in	NCT06319794Phase 2 · completed Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis · 10 trials list this drug (0 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03740100Phase 2 · terminated Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations · 10 trials list this drug (0 active)	—	—	Head and Neck Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02249429Phase 2 · completed Open-Label, Non Randomized Phase 2 Study With Safety Run-In · 10 trials list this drug (0 active)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02669511Phase 2 · completed PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma · 10 trials list this drug (0 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03127020Phase 2 · completed Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients · 10 trials list this drug (0 active)	—	—	Lymphoma,Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02483858Phase 1 · completed Study of Oral PQR309 in Patients With Advanced Solid Tumors · 10 trials list this drug (0 active)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02723877Phase 1/Phase 2 · completed PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) · 10 trials list this drug (0 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120000Phase 2 · withdrawn PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma · 10 trials list this drug (0 active)	—	—	Primary Central Nervous System Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02850744Phase 2 · terminated Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients · 10 trials list this drug (0 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01940133Phase 1 · completed A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309 · 10 trials list this drug (0 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths